在KRAS突变癌症中,Chk1-和MK2抑制剂之间的协同相互作用
Felix Dietlein1, Bastian Kalb1, Mladen Jokic1
1Department I of Internal Medicine, University Hospital Cologne, Weyertal 115B, 50931 Cologne, Germany; CECAD, University of Cologne, Weyertal 115B, 50931 Cologne, Germany.
用联合Chk1和MK2抑制剂向KRAS突变癌症显示出有希望. 这种策略诱导癌细胞死亡,为KRAS和BRAF驱动的瘤提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 克拉斯突变在人类癌症中很常见,但有效的治疗方法仍然难以捉摸.
- 向KRAS突变瘤在瘤学中是一个重大挑战.
研究的目的:
- 确定针对KRAS突变癌症的新型治疗策略.
- 研究细胞循环检查点抑制剂之间的协同相互作用.
主要方法:
- 进行了基于细胞系的选,以确定协同作用的药物组合.
- 利用异种移植和原生小鼠癌症模型进行验证.
- 分析患者衍生的瘤细胞,以评估治疗疗效.
主要成果:
- 在KRAS和BRAF驱动的癌细胞中确定了Chk1和MK2抑制剂之间的协同相互作用.
- 证明联合抑制导致KRAS突变细胞中的线粒灭绝和亡.
- 在临床前癌症模型和患者衍生细胞中验证了治疗潜力.
结论:
- 同时抑制Chk1和MK2对于KRAS或BRAF驱动的癌症是一种有前途的治疗策略.
- 这种方法针对KRAS突变瘤的内在基因毒性压力,导致癌细胞死亡.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
PI3K/mTOR/AKT Signaling Pathway
